Cleared Traditional

K170299 - Ion PGM Dx System (FDA 510(k) Clearance)

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K170299 · Life Technologies Corporation · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 2017
Decision
142d
Days
Class 2
Risk

K170299 is an FDA 510(k) clearance for the Ion PGM Dx System. Classified as High Throughput Dna Sequence Analyzer (product code PFF), Class II - Special Controls.

Submitted by Life Technologies Corporation (Carlsbad, US). The FDA issued a Cleared decision on June 22, 2017 after a review of 142 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.2265 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Life Technologies Corporation devices

Submission Details

510(k) Number K170299 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 31, 2017
Decision Date June 22, 2017
Days to Decision 142 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
54d slower than avg
Panel avg: 88d · This submission: 142d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code PFF High Throughput Dna Sequence Analyzer
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.2265
Definition A High Throughput Sequencing Technology Performing Targeted Dna Sequencing Of Amplicons From A Defined Genetic Region Or A Subset Of Genes In Human Genomic Dna From A Clinical Sample.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.